Skip to Content

Tralokinumab for adults with AD – first-time results of long-term use

More long-term treatments are needed for patients suffering from moderate-to-severe atopic dermatitis (AD). In this MEDtalk, Dermatologist Andrew Blauvelt presents promising long-term data on the safety and efficacy of tralokinumab plus optional topical corticosteroids in this group of patients.

Andrew Blauvelt

Få tilgang til artikkelen

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top